Wakefield Asset Management’s ResMed RMD Stock Holding History

Wakefield Asset Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,714	Closed	-$3.08M	–	244
2026 Q1	$3.08M	Buy	13,714 +132	+1%	+$32.9K	0.82%	39
2025 Q4	$3.27M	Sell	13,582 -8	-0.1%	-$2.05K	0.89%	38
2025 Q3	$3.72M	Sell	13,590 -821	-6%	-$224K	1.02%	30
2025 Q2	$3.72M	Sell	14,411 -242	-2%	-$57.7K	1.04%	29
2025 Q1	$3.28M	Buy	14,653 +221	+2%	+$51.6K	0.99%	32
2024 Q4	$3.3M	Buy	+14,432	New	+$3.47M	1.11%	35

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wakefield Asset Management's RMD Position: Q2 2026 in Review

Wakefield Asset Management sold out of ResMed (RMD) in Q2 2026, closing a stake of 13,714 shares — an estimated $3.08M sold.

Wakefield Asset Management first reported a position in RMD in Q4 2024 and held it in 6 quarters. The position peaked at $3.72M in Q3 2025. 889 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Wakefield Asset Management reported no remaining ResMed position as of Q2 2026 after selling out during the quarter.
Wakefield Asset Management sold 13,714 ResMed shares in Q2 2026, an estimated $3.08M.
Wakefield Asset Management first reported a position in ResMed in Q4 2024 and held it in 6 quarters.
Wakefield Asset Management's ResMed position peaked at $3.72M in Q3 2025.
889 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Wakefield Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.